Latest Breaking News On - Lantheus holdings - Page 16 : comparemela.com

16 Best Mid-Cap Growth Stocks To Buy Now

Investors are hopeful that small- and mid-cap stocks will experience a broader rally this year after getting hammered for most part of the previous year as all eyes remain focused on the Magnificent Seven.

United statesUnited kingdomVivek ramaswamyPaul marshallEric bannasch cadianWilliam blairNoah blacksteinKarim ahamedGitlab incCellular therapies incProgyny incRoivant sciences ltdCompany growth strategyShockwave medical incLantheus holdings incArtisan small cap fund

Lantheus Holdings (LNTH) Announces Acceptance of its First-to-File ANDA for Generic LUTATHERA

Lantheus Holdings (LNTH) Announces Acceptance of its First-to-File ANDA for Generic LUTATHERA
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Biopharma global incDrug administrationLantheus holdings incLantheus holdingsAbbreviated new drug application

Lantheus: FDA Accepts For Filing ANDA For Generic Version Of LUTATHERA

Lantheus Holdings, Inc. (LNTH) said its Abbreviated New Drug Application for Lutetium Lu 177 Dotatate or Lu-PNT2003, a generic version of LUTATHERA, has been accepted for filing by the FDA.

Robot corpInternational labor organizationLabor departmentEuropean commissionWorld employmentSocial outlook trendsLantheus holdings

Perspective Therapeutics Gets Equity Investment, Strategic Agreements With Lantheus

By Ben Glickman Perspective Therapeutics entered into strategic agreements with Lantheus Holdings which involve Lantheus buying a nearly 20% stake in the.

Ben glickmanLantheus holdingsInvestigational new drugArticle normalMedical equipment suppliesHealthcare life sciencesMedical diagnostic equipment suppliesMedical devices apparatusDiagnostic therapeutic devicesOwnership changesAcquisitions mergers shareholdingsAcquisitions mergersCorporate actionsCorporate industrial newsContent typesFactiva filters

Lantheus Reports Preliminary Fiscal Year 2023 Revenue

Full year 2023 worldwide revenue expected to be in the range of $1.295 – 1.297 billion, a 38 - 39% increase over the prior year including a $15 million.

United statesNew jerseyMary anne heinoMark kinarneyBiopharma global incSecurities exchangeExchange commissionLantheus holdings incChief executive officerPrivate securities litigation reform actSecurities actSecurities exchange actGlobal incRisk factorsAnnual reportsQuarterly reports